ALRT 1057, 9 CIS RETINOIC ACID IN PATIENTS W/ APML

ALRT 1057, 9 顺式视黄酸在 APML 患者中的应用

• 批准号: 6263731
• 负责人: DAN DOUER
• 金额: $ 3.56万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263731
• 关键词: clinical research; human subject; human therapy evaluation; myelogenous leukemia; neoplasm /cancer chemotherapy; retinoate; vitamin therapy

Acute promyelocytic (APL) treatment of patients has resulted in several complete remissions both in previously treated or newly diagnosed cases. The clinical safety profile of PANRETIN capsules is similar to the profile described for Tretinoin. The potential advantages of PANRETIN in APL is its effect on both types of retinoic acid receptors. PANRETIN wil be compared to Tretinoin capsules in induction of durable remissions in newly diagnosed APL cases.

急性早幼粒细胞（APL）治疗的患者已经导致了几个完全缓解，无论是在以前治疗或新诊断的情况下。 PANRETIN胶囊的临床安全性特征与维甲酸的临床安全性特征相似。 潘维汀治疗APL的潜在优势在于其对两种类型的视黄酸受体的作用。 在新诊断的APL病例中，将比较PANRETIN与维甲酸胶囊在诱导持久缓解方面的效果。